

j1
-- This application is a Divisional of and claims priority under 35 U.S.C. § 120 to U.S. Application No. 08/483,534, filed June 7, 1995 (now U.S. Patent No. 6,013,483, issued on January 11, 2000), which is hereby incorporated herein by reference in its entirety. --

In the Sequence Listing:

~~Please cancel the Substitute Sequence Listing filed with Applicants' Preliminary Amendment on December 3, 1999. Please append the paper copy of the Second Substitute Sequence Listing submitted herewith to the end of the present application and renumber the pages of the application accordingly.~~

In the Claims:

~~Please cancel claims 90 to 136 without prejudice.~~

Please add the following new claims:

137. (New) An isolated protein comprising amino acid residues 1 to 168 of SEQ ID NO:2.

j3
138. (New) The isolated protein of claim 137 wherein the amino acid sequence further comprises a heterologous polypeptide.

139. (New) The protein of claim 137 wherein said isolated protein is glycosylated.

140. (New) The protein of claim 137 wherein said isolated protein is fused to polyethylene glycol.

141. (New) A protein produced by a method comprising:

- (a) expressing the protein of claim 137 by a cell; and
- (b) recovering the protein.

142. (New) A composition comprising the isolated protein of claim 137 and a pharmaceutically acceptable carrier.

143. (New) An isolated protein comprising an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 97165;
- (b) an amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 97165; and
- (c) an amino acid sequence of the mature polypeptide encoded by the cDNA in ATCC Deposit No. 97165.

144. (New) The protein of claim 143 which comprises amino acid sequence (a).

145. (New) The protein of claim 143 which comprises amino acid sequence (b).

146. (New) The protein of claim 143 which comprises amino acid sequence (c).

147. (New) The isolated protein of claim 143 wherein the amino acid sequence further comprises a heterologous polypeptide.

148. (New) The protein of claim 143 wherein said isolated protein is glycosylated.

149. (New) The protein of claim 143 wherein said isolated protein is fused to polyethylene glycol.

150. (New) A protein produced by a method comprising:

- (a) expressing the protein of claim 143 by a cell; and
- (b) recovering the protein.

151. (New) A composition comprising the isolated protein of claim 143 and a pharmaceutically acceptable carrier.

152. (New) An isolated protein comprising an amino acid sequence 90% or more identical to amino acid residues 1 to 168 of SEQ ID NO:2.

153. (New) The isolated protein of claim 152 wherein the amino acid sequence is 95% or more identical to amino acid residues 1 to 168 of SEQ ID NO:2.

154. (New) The isolated protein of claim 152 wherein the amino acid sequence further comprises a heterologous polypeptide.

155. (New) The protein of claim 152 wherein said isolated protein is glycosylated.

156. (New) The protein of claim 152 wherein said isolated protein is fused to polyethylene glycol.

157. (New) A protein produced by a method comprising:

- (a) expressing the protein of claim 152 by a cell; and
- (b) recovering the protein.

158. (New) A composition comprising the isolated protein of claim 152 and a pharmaceutically acceptable carrier.

159. (New) An isolated protein comprising a first amino acid sequence 90% or more identical to a second amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 97165; and
- (b) an amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 97165;
- (c) an amino acid sequence of the mature polypeptide encoded by the cDNA in ATCC Deposit No. 97165.

160. (New) The isolated protein of claim 159 wherein the first amino acid sequence is 90% or more identical to the second amino acid sequence (a).

13
Cont

161. (New) The isolated protein of claim 159 wherein the first amino acid sequence is 90% or more identical to the second amino acid sequence (b).

162. (New) The isolated protein of claim 159 wherein the first amino acid sequence is 90% or more identical to the second amino acid sequence (c).

163. (New) The isolated protein of claim 159 wherein the first amino acid sequence is 95% or more identical to the second amino acid sequence (a).

164. (New) The isolated protein of claim 159 wherein the first amino acid sequence is 95% or more identical to the second amino acid sequence (b).

165. (New) The isolated protein of claim 159 wherein the first amino acid sequence is 95% or more identical to the second amino acid sequence (c).

166. (New) The isolated protein of claim 159 wherein the amino acid sequence further comprises a heterologous polypeptide.

167. (New) The protein of claim 159 wherein said isolated protein is glycosylated.

168. (New) The protein of claim 159 wherein said isolated protein is fused to polyethylene glycol.

13
cont

169. (New) A protein produced by a method comprising:

- (a) expressing the protein of claim 159 by a cell; and
- (b) recovering the protein.

170. (New) A composition comprising the isolated protein of claim 159 and a pharmaceutically acceptable carrier.

171. (New) An isolated protein comprising an amino acid sequence selected from the group consisting of:

- (a) amino acid residues 1 to 168 of SEQ ID NO:2, wherein the protein has at least one conservative substitution; and
- (b) an amino acid sequence comprising a fragment of amino acid residues 1 to 168 of SEQ ID NO:2, wherein the fragment has at least one biological activity of amino acid residues 1 to 168 of SEQ ID NO:2.

172. (New) The isolated protein of claim 171 which comprises amino acid sequence (a).

173. (New) The isolated protein of claim 171 which comprises amino acid sequence (b).

174. (New) The isolated protein of claim 171 wherein the amino acid sequence further comprises a heterologous polypeptide.

13
Cont.

175. (New) The protein of claim 171 wherein said isolated protein is glycosylated.

176. (New) The protein of claim 171 wherein said isolated protein is fused to polyethylene glycol.

177. (New) A protein produced by a method comprising:

- (a) expressing the protein of claim 171 by a cell; and
- (b) recovering the protein.

178. (New) A composition comprising the isolated protein of claim 171 and a pharmaceutically acceptable carrier.

179. (New) An isolated protein comprising an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 97165, wherein the amino acid sequence has at least one conservative substitution; and

(b) a fragment of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 97165, wherein the fragment has at least one biological activity of amino acid residues 1 to 168 of SEQ ID NO:2.

180. (New) The protein of claim 179 which comprises amino acid sequence (a).

181. (New) The protein of claim 179 which comprises amino acid sequence (b).

182. (New) The isolated protein of claim 179 wherein the amino acid sequence further comprises a heterologous polypeptide.

183. (New) The protein of claim 179 wherein said isolated protein is glycosylated.

184. (New) The protein of claim 179 wherein said isolated protein is fused to polyethylene glycol.

185. (New) A protein produced by a method comprising:

- (a) expressing the protein of claim 179 by a cell; and
- (b) recovering the protein.

186. (New) A composition comprising the isolated protein of claim 179 and a pharmaceutically acceptable carrier.

187. (New) An isolated protein comprising at least 30 contiguous amino acid residues of SEQ ID NO:2.

188. (New) The isolated protein of claim 187 wherein the isolated protein comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.

189. (New) The isolated protein of claim 187, wherein said protein has at least one biological activity of amino acid residues 1 to 168 of SEQ ID NO:2.

190. (New) The isolated protein of claim 187 wherein the amino acid sequence further comprises a heterologous polypeptide.

191. (New) The protein of claim 187 wherein said isolated protein is glycosylated.

192. (New) The protein of claim 187 wherein said isolated protein is fused to polyethylene glycol.

193. (New) A protein produced by a method comprising:

- (a) expressing the protein of claim 187 by a cell; and
- (b) recovering the protein.

194. (New) A composition comprising the isolated protein of claim 187 and a pharmaceutically acceptable carrier.

195. (New) An isolated protein comprising at least 30 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 97165.

196. (New) The isolated protein of claim 195 wherein the isolated protein comprises at least 50 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 97165.

197. (New) The isolated protein of claim 195, wherein said protein has at least one biological activity of amino acid residues 1 to 168 of SEQ ID NO:2.

13
cont

198. (New) The isolated protein of claim 195 wherein the amino acid sequence further comprises a heterologous polypeptide.

199. (New) The isolated protein of claim 195 wherein said isolated protein is glycosylated.

200. (New) The isolated protein of claim 195 wherein said isolated protein is fused to polyethylene glycol.

201. (New) A protein produced by a method comprising:

- (a) expressing the protein of claim 195 by a cell; and
- (b) recovering the protein.

202. (New) A composition comprising the isolated protein of claim 195 and a pharmaceutically acceptable carrier.

203. (New) A substantially purified polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:2.

204. (New) A substantially purified polypeptide comprising the amino acid sequence of SEQ ID NO:2.

205. (New) A pharmaceutical composition comprising at least a portion of the amino acid sequence of SEQ ID NO:2 and a pharmaceutically acceptable excipient.

13
cont

206. (New) A pharmaceutical composition comprising the amino acid sequence of SEQ ID NO:2 and a pharmaceutically acceptable excipient.
